BURLINGTON, Mass., Aug. 16, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Harlan F. Weisman, M.D., was elected to its board of directors at its Annual Meeting of Stockholders. Dr. Weisman brings over 20 years of experience as a senior healthcare executive and physician responsible for the development, regulatory approval and launch of innovative biopharmaceutical, medical device and diagnostic products. Dr. Weisman is the former Chief Science and Technology Officer for the Johnson & Johnson (J&J) Medical Devices and Diagnostics Group as well as former Company Group Chairman, Research & Development for Pharmaceuticals at J&J. "We are very excited to have Dr. Weisman join Coronado's Board of Directors. He brings broad biotechnology and pharmaceutical industry experience, which includes involvement in, and supervision of, the development and approval of numerous drug products representing well over $10 billion in annual sales," commented Dr. Bobby W. Sandage, Jr., President and CEO of Coronado. "In particular, we believe that Dr. Weisman's extensive experience with the development of treatments for a variety of autoimmune diseases, will serve us well as we advance the development of TSO and CNDO-109." Dr. Weisman is the Founder and Managing Director of And-One Consulting, LLC, a firm that assists life sciences companies develop global strategies aimed at accelerating medical product development, regulatory approval and market acceptance. Prior to his current position, Dr. Weisman was Chief Science and Technology Officer for Medical Devices and Diagnostics at J&J. In that role, he was a member of the Medical Devices and Diagnostics Group Operating Committee steering the group's scientific and technical agendas, including investments in group-level technologies, and sponsoring the research and development talent agenda. Before serving as Chief Science and Technology Officer for Medical Devices and Diagnostics, Dr. Weisman held the position of Company Group Chairman, Research & Development for Pharmaceuticals, where he had executive oversight of the ALZA Corporation, J&J Pharmaceutical Research and Development, and TransForm Pharmaceuticals, Inc. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. Dr. Weisman was also an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine.